Shares of Eli Lilly & Co. LLY rose 1.07% to $773.29 Tuesday, on what proved to be an all-around grim trading session for the ...

We recently compiled a list of the Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025. In this article, we ...

Eli Lilly and Company has invested more than $20 billion in its manufacturing capabilities since 2020 to help meet high ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day. The stock outpaced the S&P 500's daily loss of 1.11%. On the other hand, the Dow ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

High Return on Equity: With a three-year average ROE of 101% and an ROE of 123% in the last year, the company has ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...